Belgacem Chariag
Belgacem Chariag's purchase track record
Belgacem Chariag has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/10/2025 | HP | $1.01M | -29.1% | -34.6% | +5.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Ecovyst draws attention in bargain stock and EV/EBITDA screens. Ecovyst was featured in two recent Zacks selection lists, including a roundup of bargain stocks and a separate screen highlighting companies with notable EV-to-EBITDA ratios. Separately, former chief accounting officer Patti Humble was noted for joining the Exceptional Women Alliance, an industry-network recognition rather than a company event. The Zacks mentions point to valuation-based interest in ECVT, while its RSI near 39 and a well-tested support level around $12.80 provide additional context for the recent price action.
Transaction History
| HP | ▲ Buy | Grant | 5,273 | $0 | 3/5/2026 | View on chart |
| HP | ▲ Buy | Grant | 7,177 | $0 | 3/6/2025 | View on chart |
| HP | ▲ Buy | Open Market | 37,356 | $1.0M | 2/10/2025 | View on chart |
| HP | ▲ Buy | Grant | 4,675 | $0 | 2/28/2024 | View on chart |
| HP | ▲ Buy | Grant | 4,197 | $0 | 3/1/2023 | View on chart |
| HP | ▲ Buy | Grant | 4,733 | $0 | 3/2/2022 | View on chart |
| ECVT | ▲ Buy | Grant | 142,765 | $0 | 3/1/2022 | View on chart |
| ECVT | ▲ Buy | Grant | 291,546 | $0 | 1/17/2022 | View on chart |
| ECVT | ▲ Buy | Grant | 194,363 | $0 | 1/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Susquehanna Raises Helmerich & Payne Price Target to $50
Susquehanna has maintained a positive outlook on Helmerich & Payne and raised its price target to $50. This move places the firm at the top of the current analyst consensus range, which averages $44.75. The stock is currently trading near its 200-day moving average, with the new target sitting above the recent 52-week high.
Susquehanna Raises Helmerich & Payne Price Target to $50. Susquehanna has maintained a positive outlook on Helmerich & Payne and raised its price target to $50. This move places the firm at the top of the current analyst consensus range, which averages $44.75. The stock is currently trading near its 200-day moving average, with the new target sitting above the recent 52-week high.